Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Recon 2.2: from reconstruction to model of human metabolism.

Swainston N, Smallbone K, Hefzi H, Dobson PD, Brewer J, Hanscho M, Zielinski DC, Ang KS, Gardiner NJ, Gutierrez JM, Kyriakopoulos S, Lakshmanan M, Li S, Liu JK, Martínez VS, Orellana CA, Quek LE, Thomas A, Zanghellini J, Borth N, Lee DY, Nielsen LK, Kell DB, Lewis NE, Mendes P.

Metabolomics. 2016;12:109. Epub 2016 Jun 7.

2.

SYNBIOCHEM-a SynBio foundry for the biosynthesis and sustainable production of fine and speciality chemicals.

Carbonell P, Currin A, Dunstan M, Fellows D, Jervis A, Rattray NJ, Robinson CJ, Swainston N, Vinaixa M, Williams A, Yan C, Barran P, Breitling R, Chen GG, Faulon JL, Goble C, Goodacre R, Kell DB, Feuvre RL, Micklefield J, Scrutton NS, Shapira P, Takano E, Turner NJ.

Biochem Soc Trans. 2016 Jun 15;44(3):675-7. doi: 10.1042/BST20160009. Review.

3.
4.

Fitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can Fly.

Mendes P, Oliver SG, Kell DB.

Trends Pharmacol Sci. 2015 Nov;36(11):710-23. doi: 10.1016/j.tips.2015.07.006. Epub 2015 Nov 1. Review.

5.
6.

Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites.

O'Hagan S, Kell DB.

Front Pharmacol. 2015 May 13;6:105. doi: 10.3389/fphar.2015.00105. eCollection 2015.

7.

The dormant blood microbiome in chronic, inflammatory diseases.

Potgieter M, Bester J, Kell DB, Pretorius E.

FEMS Microbiol Rev. 2015 Jul;39(4):567-91. doi: 10.1093/femsre/fuv013. Epub 2015 May 3. Review.

8.

Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics.

Pretorius E, Bester J, Vermeulen N, Alummoottil S, Soma P, Buys AV, Kell DB.

Cardiovasc Diabetol. 2015 Mar 8;14:30. doi: 10.1186/s12933-015-0192-5.

9.

A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs.

O Hagan S, Swainston N, Handl J, Kell DB.

Metabolomics. 2015;11(2):323-339. Epub 2014 Sep 19.

10.

Molecular phenotyping of a UK population: defining the human serum metabolome.

Dunn WB, Lin W, Broadhurst D, Begley P, Brown M, Zelena E, Vaughan AA, Halsall A, Harding N, Knowles JD, Francis-McIntyre S, Tseng A, Ellis DI, O'Hagan S, Aarons G, Benjamin B, Chew-Graham S, Moseley C, Potter P, Winder CL, Potts C, Thornton P, McWhirter C, Zubair M, Pan M, Burns A, Cruickshank JK, Jayson GC, Purandare N, Wu FC, Finn JD, Haselden JN, Nicholls AW, Wilson ID, Goodacre R, Kell DB.

Metabolomics. 2015;11:9-26. Epub 2014 Jul 25.

11.

The virtue of innovation: innovation through the lenses of biological evolution.

Kell DB, Lurie-Luke E.

J R Soc Interface. 2015 Feb 6;12(103). pii: 20141183. doi: 10.1098/rsif.2014.1183.

12.

Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.

Currin A, Swainston N, Day PJ, Kell DB.

Chem Soc Rev. 2015 Mar 7;44(5):1172-239. doi: 10.1039/c4cs00351a. Review.

13.

Eryptosis as a marker of Parkinson's disease.

Pretorius E, Swanepoel AC, Buys AV, Vermeulen N, Duim W, Kell DB.

Aging (Albany NY). 2014 Oct;6(10):788-819.

14.

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.

Kell DB, Oliver SG.

Front Pharmacol. 2014 Oct 31;5:231. doi: 10.3389/fphar.2014.00231. eCollection 2014. Review.

15.

Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes.

Anderson SG, Dunn WB, Banerjee M, Brown M, Broadhurst DI, Goodacre R, Cooper GJ, Kell DB, Cruickshank JK.

PLoS One. 2014 Sep 3;9(9):e103217. doi: 10.1371/journal.pone.0103217. eCollection 2014.

16.

SpeedyGenes: an improved gene synthesis method for the efficient production of error-corrected, synthetic protein libraries for directed evolution.

Currin A, Swainston N, Day PJ, Kell DB.

Protein Eng Des Sel. 2014 Sep;27(9):273-80. doi: 10.1093/protein/gzu029. Epub 2014 Aug 9.

17.

Event-based text mining for biology and functional genomics.

Ananiadou S, Thompson P, Nawaz R, McNaught J, Kell DB.

Brief Funct Genomics. 2015 May;14(3):213-30. doi: 10.1093/bfgp/elu015. Epub 2014 Jun 6. Review.

18.

GeneGenie: optimized oligomer design for directed evolution.

Swainston N, Currin A, Day PJ, Kell DB.

Nucleic Acids Res. 2014 Jul;42(Web Server issue):W395-400. doi: 10.1093/nar/gku336. Epub 2014 Apr 29.

19.

Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Pretorius E, Bester J, Vermeulen N, Lipinski B, Gericke GS, Kell DB.

PLoS One. 2014 Jan 9;9(1):e85271. doi: 10.1371/journal.pone.0085271. eCollection 2014.

20.

High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.

Bester J, Buys AV, Lipinski B, Kell DB, Pretorius E.

Front Aging Neurosci. 2013 Dec 6;5:88. doi: 10.3389/fnagi.2013.00088. eCollection 2013.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk